<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574844</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A02709-44</org_study_id>
    <nct_id>NCT03574844</nct_id>
  </id_info>
  <brief_title>Effect of Oral Probiotic Yeast on the Composition of the Vaginal Microbiota in Healthy Women</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Effect of Oral Probiotic Yeast on the Composition of the Vaginal Microbiota in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lesaffre International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biofortis Mérieux Nutriscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lesaffre International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the impact of oral consumption of the probiotic yeast CNCM
      I-3856 on healthy vaginal microbiota
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, 3 parallel-arms, pilot clinical study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>S cerevisiae transfer from the gut to the vagina</measure>
    <time_frame>Day 28</time_frame>
    <description>Proportion of subjects presenting the yeast strain S cerevisiae CNCM I-3856 (presence) in their vaginal microbiota after a 4-week daily supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>S cerevisiae transfer from the gut to the vagina</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 42</time_frame>
    <description>Proportion of subjects presenting the yeast strain S cerevisiae CNCM I-3856 (presence) in their vaginal microbiota after 1, 2 or 3-week daily supplementation and after a 2-week observation period without supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of S cerevisiae in the vagina</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 42</time_frame>
    <description>Value at Day 7, 14, 21, 28, 42 and change Day 42 - Day 28 of S cerevisiae CNCM I-3856 (CFU/ sample) in the vaginal microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on 4 predominant Lactobacilli species</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 42</time_frame>
    <description>Changes of 4 dominant Lactobacilli species (number of copies per sample) by comparison of the 3 groups at each time change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between intestinal and vaginal microbiota for the presence of S cerevisiae CNCM I-3856</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 42</time_frame>
    <description>Evaluation of the presence of S cerevisiae CNCM I-3856 in the vaginal microbiota considering its presence in the intestinal microbiota in each active group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the quantity of S cerevisiae CNCM I-3856 (CFU/sample) in the intestinal microbiota and vaginal microbiota</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 42</time_frame>
    <description>Correlation between the quantity of S cerevisiae CNCM I-3856 (CFU/sample) in the intestinal microbiota and vaginal microbiota in each active group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Candida albicans in the vaginal microbiota</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 42</time_frame>
    <description>In each group, at each time point according to Day 0 and at Day 42 according to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the presence of Candida albicans in the vaginal microbiota</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 42</time_frame>
    <description>Changes of Candida albicans (CFU/samples) in the vaginal microbiota</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Vaginal Health</condition>
  <arm_group>
    <arm_group_label>Saccharomyces cerevisiae, dose 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saccharomyces cerevisiae, dose 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces cerevisiae, dose 500</intervention_name>
    <description>Experimental arm</description>
    <arm_group_label>Saccharomyces cerevisiae, dose 500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces cerevisiae, dose 1000</intervention_name>
    <description>Experimental arm</description>
    <arm_group_label>Saccharomyces cerevisiae, dose 1000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian or Asian women,

          -  With regular menstrual cycles, assessed as 28 days ± 3 days,

          -  With a normal vaginal flora : Nugent score ≤ 3,

          -  With the same efficient contraception method since at least 3 months before the start
             of the study, and accepting to maintain this program over the study. Authorized
             contraception methods: hormonal contraception (pill, patch, implant and intrauterine
             device), tubal ligation, ESSURE system and copper intrauterine device (without
             hormone),

          -  Agreeing to keep unchanged her intimate hygiene rules during the all duration of the
             study (same stable intimate hygiene habits since at least 3 months before the start of
             the study),

          -  Good general and mental health compatible with the study participation and allowing to
             be followed in ambulatory way according to the investigator opinion: no clinically
             significant and relevant abnormalities of medical history or physical examination;

          -  Having stable life habits since at least 3 months and accepting to maintain them
             stable during the study (dietary habits, tobacco and alcohol consumptions, physical
             activity and sexual activity),

          -  Tobacco consumption ≤ 10 cigarettes per day,

          -  Able and willing to participate to the study by complying with the protocol procedures
             (especially concerning study product consumption and biological samples collections),
             as evidenced by her dated and signed informed consent form,

          -  Affiliated with a social security scheme,

          -  Agreeing to be registered on the national file of volunteers participating in
             biomedical research.

        Exclusion Criteria:

          -  Having hypersensitivity history to one of the ingredients of the study products,

          -  Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble
             or other uncontrolled metabolic disorder,

          -  Suffering from a severe chronic disease (e.g. cancer, renal failure, hepatic or
             biliary disorders ongoing, chronic inflammatory digestive disease, arthritis, chronic
             respiratory trouble, chronic gastro-intestinal disorder, cardiac disease,
             immunodeficiency…) or diseases found to be inconsistent with the conduct of the study
             by the investigator (controlled arterial hypertension accepted),

          -  Suffering from Sexually Transmitted Infection (STI) or Disease (STD) such as HIV
             (Human Immunodeficiency Virus), B and C hepatitis, HPV (Human PapillomaVirus),
             Chlamydia infection, syphilis, gonorrhea, genital herpes, etc,

          -  Currently suffering or having suffer from bacterial, fungal, parasitic or viral
             infection of the uro-gynecological sphere (vaginitis, cystitis, cervix infection…),
             treated or not, in the 6 months previous to the study start,

          -  Having medical history or current pathology which could affect the study results or
             expose the subject to an additional risk according to the investigator,

          -  Currently pregnant, or lactating, intending to be pregnant within 2 months ahead or
             pregnancy and/or breastfeeding finished since less than 3 months,

          -  Ongoing symptoms of vaginal and/or urinary infection (belong to symptoms
             questionnaire) at the moment of the V0 and V1 visits,

          -  Recent history of radiotherapy (less than 6 months),

          -  Menopausal or pre-menopausal,

          -  With menstruation which usually lasts more than 7 days,

          -  Under chronic treatment with corticosteroids and/or immune modulator (immunostimulant,
             immunosuppressant…) or last intake within 3 months before the start of the study,

          -  Currently under medication or dietary supplement, oral or local, which could affect
             study parameters: antibiotic, antifungal, probiotic, prebiotic, symbiotic,
             phytoestrogens, etc, or stopped within a too short time window before study start
             (less than 4 weeks) ,

             .- Having a lifestyle deemed incompatible with the study according to the investigator
             (specific diet (vegetarian, vegan, hypocolaric…), alcohol consumption &gt; 2 glasses /
             day, physical activity &gt; 10 hours / week…),

          -  With a personal history of anorexia nervosa, bulimia or significant eating disorders
             according to the investigator,

          -  Planning to travel for a long time during the study duration or not able to be
             contacted for emergency reason during the study available,

          -  Presenting a psychological or linguistic incapacity to understand and sign the
             informed consent,

          -  Participating in another clinical trial or in exclusion period from a previous
             clinical trial,

          -  Having received, during the last 12 months, countervailing indemnities for clinical
             trial higher or equal to 4500 Euros,

          -  Under legal protection (guardianship, wardship) or deprived from her rights following
             judicial or administrative decision.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biofortis Mérieux Nutriscience</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

